KURA
Kura Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KURA
Kura Oncology, Inc.
A clinical-stage biopharmaceutical company that develops therapeutics for the treatment of solid tumors and blood cancers
12730 High Bluff Drive, Suite 400, San Diego, CA 92130
--
Kura Oncology, Inc., was originally incorporated in Delaware in November 2007. They are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicine to treat cancer. Their pipeline consists of small molecule product candidates targeting cancer signaling pathways where there are strong scientific and clinical reasons to improve outcomes, which they intend to combine with molecular or cellular diagnosis to identify patients most likely to respond to treatment. They are conducting clinical trials on three product candidates: ciftominib, tipifarnib and KO-2806.
Earnings Call
Q1/2025
Estimate EPS-0.6
Actual EPS-0.66
Estimate Revenue39.08M
Actual Revenue14.11M
Kura Oncology's Q1 2025: Navigating Contradictions in Regulatory Approvals and Market Strategy
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
KURA has released its 2025 Q3 earnings. EPS was reported at -0.85, versus the expected -0.68, missing expectations. The chart below visualizes how KURA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KURA has released its 2025 Q3 earnings report, with revenue of 20.75M, reflecting a YoY change of NaN%, and net profit of -74.12M, showing a YoY change of -36.23%. The Sankey diagram below clearly presents KURA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
